Radiation Oncology Journal

The Korean Society for Radiation Oncology (대한방사선종양학회)
권호 표지

The Clinical Significance of Cathepsin D and p53 Expression in Locally Advanced Rectal Cancer

국소진행된 직장암에서 Cathepsin D와 p53 발현의 임상적 의의

  • Kim, Jun-Sang (Departments of Radiation Oncology, College of Medicine, Chungnam National University) ;
  • Lee, Sheng-Jin (Departments of Pathology, College of Medicine, Chungnam National University) ;
  • Kim, Jin-Man (Departments of Pathology, College of Medicine, Chungnam National University) ;
  • Cho, Moon-June (Departments of Radiation Oncology, College of Medicine, Chungnam National University)
  • 김준상 (충남대학교 의과대학 방사선종양학교실) ;
  • 이생금 (충남대학교 의과대학 병리학교실) ;
  • 김진만 (충남대학교 의과대학 암공동연구소) ;
  • 조문준 (충남대학교 의과대학 방사선종양학교실)
  • Published : 2008.03.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Cathepsin D(CD) is a lysosomal acid proteinase that is related to malignant progression, invasion, and a poor prognosis in several tumors. The aim of this study was to evaluate the prognostic clinical significance of CD and p53 expression in pretreatment biopsy specimens from patients with locally advanced rectal cancer who were treated with preoperative chemoradiation. Materials and Methods: Eighty-nine patients with locally advanced rectal cancer(cT3/T4 or N+) were included in this study. Preoperative chemoradiation consisted of a dose of 50.4 Gy of pelvic radiation and two concurrent cycles of administration of 5-fluorouracil and leucovorin. Surgery was performed six weeks after chemoradiation. CD and p53 expression in pretreatment formalin-fixed paraffin-embedded tumor biopsy specimens were assessed by immunohistochemical staining using a CD and p53 monoclonal antibodies. The threshold value for a positive stain in tumor tissue and stromal cells was 1+ intensity in 10% of the tumors or stromal cells, respectively. Results: Positive CD expression was found in 57(64%) of the tumors and 32(35%) of the stromal cell specimens. There was no association with CD expression of the tumor or stromal cells and patient characteristics. There was a correlation between tumor CD expression with stromal cell CD expression(p=0.01). Overexpression of p53 was not a significant prognostic factor. The 5-year overall survival(OS) and disease-free survival(DFS) rates were not different between tumor CD-negative and positive patient biopsy samples(69% vs. 65%, 60% vs. 61%, respectively). The 5-year OS rates in the tumor-negative/stromal cell-negative, tumor-negative/stromal cell-positive, tumor-positive/stromal cell-negative and tumor-positive/stromal cell-positive biopsy samples were 75%, 28%, 62%, and 73%, respectively. Stromal cell staining only without positive tumor staining demonstrated the worst overall survival prognosis for patients(p=0.013). Conclusion: Overexpression of p53 in rectal biopy tissue was not associated with prognostic significance. In the pretreatment biopsy specimens, an exclusive increase in CD expression in stromal cells without tumor expression was related to poor overall survival in patients with locally advanced rectal cancer treated with preoperative chemoradiation.

목적: 본 연구는 수술 전 방사선화학요법을 시행 받은 국소진행된 직장암환자에서 치료 전 얻어진 직장암 생검조직 내에서의 cathepsin D(CD) 및 p53의 발현이 갖는 예후적 인자를 포함한 임상적 의의에 대하여 알아보고자 하였다. 대상 및 방법: 1993년 7월부터1999년 6월까지 국소진행된 직장암으로 수술 전 방사선화학요법을 시행 받은 127명의 환자 중 근치적 수술을 시행 받았고 수술 전 생검 조직의 파라핀 블록을 얻을 수 있던 89명의 환자를 대상으로 하였다. 방사선치료는 하루 1.8 Gy씩 주 5회, 25회에 걸쳐 전 골반 부위에 45 Gy까지 조사한 후에 원발종양 부위에만 5.4 Gy 추가 조사하였다. 화학요법은 5-Fluorouracil과 Leucovorin을 5일간 일시 정주하였고 방사선치료기간 1주 및 5주째 투여하였으며 방사선치료 종료 후 약 6주경에 근치적 절제술을 시행하였다. Mouse 단클론 항체인 CD와 p53을 이용하여 면역염색을 시행하였다. CD 및p53이 종양세포 및 종양기질세포에 10% 이상 발현 시 양성으로 판정하였다. 결과: 종양세포내 CD 발현은 57명(64%)이 양성이었고 종양기질세포내 양성은 71명(80%)이었다. p53의 종양세포내 발현은 35명(39%)이 양성을 보였다. 성별, 환자나이, 종양의 운동성, 종양의항문 연으로부터의 거리, 임상적 TNM 병기에 따라 종양세포 및 종양기질세포내 CD 발현 및 p53 발현의 통계적 차이가 없었다. 종양세포와 종양기질세포내 CD발현 사이에 양적인 상호 연관성이 있었다(p=0.01). 종양세포내 CD발현과 p53의 발현은 통계적인 상호관련성이 없었다(p=0.79). 단변량분석 및 다변량분석 상 5년 전체생존율 및 무병생존율에 대한 예후인자로서 종양세포 및 종양기질세포내 CD 발현과 p53은 통계적 유의성이 없었다. 그러나 종양세포 및 종양기질세포내 CD 발현에 따른 하위집단 생존율 분석상 종양세포 및 종양기질세포내 CD 발현이 음성인 경우가 5년 전체생존율이 75%로서 가장 높았으며 종양기질세포내에만 CD가 발현된 경우는 5년 전체생존율 29%로서 가장 낮았다(p=0.01). 결론: 수술 전 방사선화학요법을 시행 받은 국소진행된 직장암 환자에서 치료 전 직장암 생검조직 내에서의 p53 발현은 유의한 생존예후인자는 아니었으며 CD가 종양세포에는 발현되지 않고 종양기질세포에만 발현 시 전체생존율에 불량한 예후인자였다.

Keywords

References

  1. Korean National Statistical Office. Annual report on the cause of death statistic in 2005. 2006
  2. Janjan NA, Khoo VS, Abbruzzese J, et al. Tumor downstaging andsphincter preservation with preoperative chemoradiation in locally advanced rectal cancer: The M.D. Anderson Cancer Center experience. Int J Radiat Oncol Biol Phys 1999;44:1027-1038 https://doi.org/10.1016/S0360-3016(99)00099-1
  3. Minsky BD, Cohen AM, Enker WE, et al. Preoperative 5-FU, low-dose leucovorin, and radiation therapy for locally advanced and unresectable rectal cancer. Int J Radiat Oncol Biol Phys 1997;37:289-295 https://doi.org/10.1016/S0360-3016(96)00487-7
  4. Sauer R, Becker H, Hohenberger W, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-1740 https://doi.org/10.1056/NEJMoa040694
  5. Kim JS, Kim JS, Cho MJ, Song KS, Yoon WH. Preoperative chemoradiation using oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 2002;54:403-408 https://doi.org/10.1016/S0360-3016(02)02856-0
  6. Li S, Kim JS, Kim JM, et al. Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2006;65:705-712 https://doi.org/10.1016/j.ijrobp.2006.01.013
  7. Chabowski A, Skrzydlewska E, Sulkowska M, et al. Cathepsin D activity in colorectal cancer. Ann Acad Med Bialostoc 2001;46:38-46
  8. Chabowski A, Sulkowska M, Sulkowski S, Famulski W, Skrzydlewska E, Kisielewski W. Immunohistochemical evaluation of cathepsin D expression in colorectal cancer. Folia Histochem Cytobiol 2001;39:153-154
  9. van der Stappen JW, Williams AC, Maciewicz RA, Paraskeva C. Activation of cathepsin B, secreted by a colorectal cancer cell line requires low pH and is mediated by cathepsin D. Int J Cancer 1996;67:547-554 https://doi.org/10.1002/(SICI)1097-0215(19960807)67:4<547::AID-IJC14>3.0.CO;2-4
  10. Rochefort H, Garcia M, Glondu M, et al. Cathepsin D in breast cancer: mechanisms and clinical applications, a 1999 overview. Clin Chim Acta 2000;291:157-170 https://doi.org/10.1016/S0009-8981(99)00226-0
  11. Oh-e H, Tanaka S, Kitadai Y, Shimamoto F, Yoshihara M, Haruma K. Cathepsin D expression as a possible predictor of lymph node metastasis in submucosal colorectal cancer. Eur J Cancer 2001;37:180-188 https://doi.org/10.1016/S0959-8049(00)00348-8
  12. Ikeguchi M, Fukuda K, Oka S, et al. Clinicopathological significance of cathepsin D expression in gastric adenocarcinoma. Oncology 2001;61:71-78 https://doi.org/10.1159/000055356
  13. Ioachim E, Charchanti A, Stavropoulos N, Athanassiou E, Bafa M, Agnantis NJ. Expression of cathepsin D in urothelial carcinoma of the urinary bladder: an immunohistochemical study including correlations with extracellular matrix components, CD44, p53, Rb, c-erbB-2 and the proliferation indices. Anticancer Res 2002;22:3383-3388
  14. Ferrandina G, Scambia G, Bardelli F, Benedetti Panici P, Mancuso S, Messori A. Relationship between cathepsin D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer 1997;76:661-666 https://doi.org/10.1038/bjc.1997.442
  15. Riley LB, Lange MK, Browne J, et al. Analysis of cathepsin D in human breast cancer: Usefulness of the processed 31 ku active form of the enzyme as a prognostic indicator in node-negative and node-positive patients. Breast Cancer Res Treat 2000;60:173-179 https://doi.org/10.1023/A:1006394401199
  16. Talieri M, Papadopoulou S, Scorilas A, et al. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Letters 2004;205:97-106 https://doi.org/10.1016/j.canlet.2003.09.033
  17. Lane DP. p53, guardian of the genome. Nature 1992;358:15-16 https://doi.org/10.1038/358015a0
  18. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: a systematic review. Br J Cancer 2005;92:434-444 https://doi.org/10.1038/sj.bjc.6602358
  19. Morgan M, Koorey D, Painter D, et al. p53 and DCC immunohistochemistry in curative rectal cancer surgery. Int J Colorectal Dis 2003;18:188-195
  20. Duffy MJ. Role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 1992;10:145-155 https://doi.org/10.1007/BF00132746
  21. Rochefort H. Cathepsin D in breast cancer. Breast Cancer Res Treat 1990;16:3-13 https://doi.org/10.1007/BF01806570
  22. Berchem G, Glondu M, Gleizes M, et al. Cathepsin-D affects multiple tumor progression steps in vivo: proliferation, angiogenesis and apoptosis. Oncogene 2002;21:5951-5955 https://doi.org/10.1038/sj.onc.1205745
  23. Rochefort H, Liaudet-Coopman E. Cathepsin D in cancer metatasis: a protease and a ligand. APMIS 1999;107:86-95 https://doi.org/10.1111/j.1699-0463.1999.tb01530.x
  24. Sebzda T, Saleh Y, Gburek J, et al. Cathepsin D expression in human colorectal cancer: relationship with tumour type and tissue differentiation grade. J Exp Ther Oncol 2005;5:145-150
  25. Talieri M, Papadopoulou S, Scorilas A, et al. Cathepsin B and cathepsin D expression in the progression of colorectal adenoma to carcinoma. Cancer Lett 2004;205:97-106 https://doi.org/10.1016/j.canlet.2003.09.033
  26. Kanber Y, Demirbag NR, Sam AD, Aydin N. Cathepsin D expression in colorectal adenocarcinomas and adenomas. Int J Biol Markers 2002;17:165-168 https://doi.org/10.1177/172460080201700304
  27. Theodoropoulos GE, Panoussopoulos D, Lazaris AC, Golematis BC. Evaluation of cathepsin D immunostaining in colorectal adenocarcinoma. J Surg Oncol 1997;65:242-248 https://doi.org/10.1002/(SICI)1096-9098(199708)65:4<242::AID-JSO4>3.0.CO;2-5
  28. Sis B, Sagol O, Kupelioglu A, et al. Prognostic significance of matrix metalloproteinase-2, cathepsin D, and tenascin-C expression in colorectal carcinoma. Pathol Res Pract 2004;200:379-387 https://doi.org/10.1016/j.prp.2004.02.012
  29. Ioachim E, Kitsiou E, Charalabopoulos K, et al. Immunohistochemical evaluation of cathepsin D in normal, hyperplastic and malignant endometrium: correlation with hormone receptor status c-erbB-2, p53, Rb proteins and proliferation associated indices. Int J Gynecol Cancer 2003;13:344-351 https://doi.org/10.1046/j.1525-1438.2003.13181.x
  30. Wu GS, Saftig P, Peters C, El-Deiry WS. Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. Oncogene 1998;16:2177-2183 https://doi.org/10.1038/sj.onc.1201755
  31. Ioachim EE, Goussia AC, Machera M, Tsianos EV, Kappas AM, Agnantis NJ. Immunohistochemical evaluation of cathepsin D expression in colorectal tumours: a correlation with extracellular matrix components, p53, pRb, bcl-2, c-erbB-2, EGFR and proliferation indices. Anticancer Res 1999;19:2147-2155
  32. Wiggenraad R, Tamminga R, Blok P, Rouse R, Hermans J. The prognostic significance of p53 expression for survival and local control in rectal carcinoma treated with surgery and postoperative radiotherapy. Int J Radiat Oncol Biol Phys 1998;41:29-35 https://doi.org/10.1016/S0360-3016(98)00043-1
  33. Gallego MG, Acenero MJ, Ortege S, Delgdo AA, Cantero JL. Prognostic influence of p53 nuclear overexpression in colorectal carcinoma. Dis Colon Rectum 2000;43:971-975 https://doi.org/10.1007/BF02237362
  34. Choi C, Kim M, Yoo S, et al. The clinicopathological factors that determine a local recurrence of rectal cancers that have been treated with surgery and chemoradiotherapy. J Korean Soc Ther Radiol Oncol 2006;24:255-262
  35. Tannapfel A, Nusslein S, Fietkau R, Katalinic A, Kockerling F, Wittekind C. Apoptosis, proliferation, bax, bcl-2 and p53 status prior to and after preoperative radiochemotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 1998;41:585-591 https://doi.org/10.1016/S0360-3016(98)00076-5